ACE inhibitor pathway (WP468)

Danio rerio

The renin-angiotensin-aldosterone system (RAAS) is central to the control of blood pressure and the target of several types of anti-hypertensive drugs. This pathway depicts a simplified representation of the pharmacodynamics (PD) of RAAS-acting drugs including candidate genes for the pharmacogenomics (PGx) of ACE inhibitors, angiotensin receptor blockers (ARBs), renin inhibitor aliskiren and aldosterone receptor antagonists. Source: PharmGKB (


Caroline F. Thorn , Thomas Kelder , Kristina Hanspers , Egon Willighagen , Christine Chichester , Martina Summer-Kutmon , and Eric Weitz


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Danio rerio



Pathway Ontology

ACE inhibitor drug pathway


Label Type Compact URI Comment
Bradykinin Metabolite hmdb:HMDB0004246
Aldosterone Metabolite kegg.compound:C01780
ACE Inhibitor Metabolite chebi:35457
Angiotensin II Metabolite hmdb:HMDB0001035
Angiotensin I Metabolite pubchem.compound:3081372
ren GeneProduct ncbigene:405786
bdkrb2 GeneProduct ncbigene:368199
agt GeneProduct ncbigene:322485
kng1 GeneProduct ncbigene:449808
agtr1 GeneProduct ncbigene:561935
agtr2 GeneProduct ncbigene:503772
ace2 GeneProduct ncbigene:492331
ace2 GeneProduct ncbigene:492331


  1. The emerging role of ACE2 in physiology and disease. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus ADME, et al. J Pathol. 2007 May;212(1):1–11. PubMed Europe PMC Scholia